Alterity Therapeutics Granted ATH434 Patent to Treat Neurodegenerative Diseases
· smallcaps.com.au
Alterity Therapeutics wins US patent for ATH434, extending protection to 2045 and backing Phase 3 push in MSA/Parkinsons, lifting ATH upside.
The US Patent and Trademark Office has granted a gold standard patent for Alterity Therapeutics’ (ASX: ATH) lead clinical asset ATH434 to treat the underlying...